Journal of Clinical Oncology, Vol 1, 251-254, Copyright © 1983 by American Society of Clinical Oncology

ARTICLES

Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy

N Jaffe, E Smith, HT Abelson and E Frei 3d

The number and time to appearance of pulmonary metastases were evaluated in 15 patients with osteogenic sarcoma receiving adjuvant chemotherapy with high-dose methotrexate and doxorubicin (adjuvant group). The results were compared to 33 age- and sex-matched controls (control group). The adjuvant group demonstrated a reduction in the number and a delay in the appearance of the metastases. The median time to development of metastases was 17 mo in the adjuvant group and 7 mo in the control group, and the median number of metastases was 2 and 12, respectively.

This article has been cited by other articles:

				R. M. Suri, C. Deschamps, S. D. Cassivi, F. C. Nichols III, M. S. Allen, C. D. Schleck, and P. C. Pairolero Pulmonary Resection for Metastatic Malignant Fibrous Histiocytoma: An Analysis of Prognostic Factors Ann. Thorac. Surg., November 1, 2005; 80(5): 1847 - 1852. [Abstract] [Full Text] [PDF]

				L. Aung, R. Gorlick, J. H. Healey, W. Shi, H. T. Thaler, N. A. Shorter, A. G. Huvos, and P. A. Meyers Metachronous Skeletal Osteosarcoma in Patients Treated with Adjuvant and Neoadjuvant Chemotherapy for Nonmetastatic Osteosarcoma J. Clin. Oncol., January 15, 2003; 21(2): 342 - 348. [Abstract] [Full Text] [PDF]

				The International Registry of Lung Metastases, Writing Committee:, U. Pastorino, M. Buyse, G. Friedel, R. J. Ginsberg, P. Girard, P. Goldstraw, M. Johnston, P. McCormack, et al. LONG-TERM RESULTS OF LUNG METASTASECTOMY: PROGNOSTIC ANALYSES BASED ON 5206 CASES J. Thorac. Cardiovasc. Surg., January 1, 1997; 113(1): 37 - 49. [Abstract] [Full Text]